N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
NCT ID: NCT07217496
Last Updated: 2026-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
18 participants
INTERVENTIONAL
2026-02-15
2027-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
NCT07221942
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
NCT06470282
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
NCT04878029
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
NCT05775471
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT04164082
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the safety and tolerability of the treatment regimen (N-803, enfortumab vedotin, and pembrolizumab).
II. To assess 12-month progression-free survival (PFS) of participants with locally advanced or metastatic urothelial carcinoma (mUC) receiving enfortumab vedotin (EV) plus pembrolizumab and N-803.
SECONDARY OBJECTIVE:
I. To evaluate the preliminary efficacy of the treatment regimen (EV, pembrolizumab, and N-803) as measured by complete response rate (CRR), objective response rate (ORR), clinical benefit rate (CBR), 12-month overall survival (12-OS), median duration of response (mDOR), median progression-free survival (mPFS) and median overall survival (mOS).
EXPLORATORY OBJECTIVES:
I. To determine the immune status of the tumor microenvironment using multiplex immunohistochemistry (IHC) and identify potential correlations with participant outcomes.
II. To determine T-cell receptor (TCR) clonality.
III. To analyze tumor/immune gene expression profiles, DNA methylation, DNA damage response and repair (DDR) genes \[e.g., BRCA1/2, ERCC1/2\]).
IV. Observe changes in circulating tumor DNA (ctDNA).
V. To monitor the maintenance of absolute lymphocyte counts (ALC) relative to baseline, throughout the course of treatment.
OUTLINE:
This is an open-label, single center, phase Ib single-arm trial with a safety lead-in cohort. Participants will receive treatment for up to 12 cycles administered. Depending on response, participants may continue treatment with pembrolizumab and N-803 for maximum of 2 years. Participants will undergo safety follow-up approximately 30 days following the end of study treatment and be followed for survival until death (any cause) or end of study for a up to 5 years from start of treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (EV, N-803, pembrolizumab)
Participants with unresectable locally advanced (LA) or metastatic urothelial carcinoma (mUC) will receive N-803 plus Enfortumab Vedotin (EV) and Pembrolizumab on Day 1 and EV on Day 8 in a repeated 3-week cycle until disease progression or unacceptable toxicity. EV treatment is provided up to 12 cycles. Participants with confirmed clinical benefit based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) at the second or third scan (between 8 to 12 cycles on treatment) will discontinue EV treatment at investigator discretion. After participants discontinue EV treatment, participants may continue to receive N-803 and Pembrolizumab treatment up to 2 years.
Nogapendekin Alfa Inbakicept (N803)
Given subcutaneously (SC)
Enfortumab Vedotin (EV)
Given intravenously (IV)
Pembrolizumab
Given intravenously (IV)
Research Biospecimen Collection
Undergo blood collection for research purposes
Radiographic Imaging
Undergo radiographic imaging for disease assessment
Tumor Biopsy
Undergo tumor biopsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nogapendekin Alfa Inbakicept (N803)
Given subcutaneously (SC)
Enfortumab Vedotin (EV)
Given intravenously (IV)
Pembrolizumab
Given intravenously (IV)
Research Biospecimen Collection
Undergo blood collection for research purposes
Radiographic Imaging
Undergo radiographic imaging for disease assessment
Tumor Biopsy
Undergo tumor biopsy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically or cytologically confirmed locally advanced (LA)/ metastatic urothelial carcinoma (mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra. Mixed-cell type tumors are eligible as long as \> 50% urothelial component is present (mixed histology other than small cell/ neuroendocrine are allowed).
3. No prior systemic treatment for LA/mUC.
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) \<= 2.
5. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
6. Prior perioperative systemic therapy including neoadjuvant or adjuvant chemotherapy, immune checkpoint inhibitors, and EV is allowed if treatment was completed \> 12 months before trial enrollment.
7. Participants enrolling in the trial must agree with discontinuing EV upon demonstrating confirmed CR/PR/SD at the second or third scan timepoint on treatment (after 5.5 to 8 months of intended EV treatment).
8. Leukocytes ≥ 3,000/microliter (uL).
9. Absolute neutrophil count (ANC) ≥ 1,500/uL.
10. Platelets ≥ 100,000/uL.
11. Total bilirubin \< 1.5 x institutional upper limit of normal (ULN) (if previously abnormal due to non-malignant causes such as Gilbert's disease bilirubin ≤ 2 x ULN will be permitted.)
12. Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase (SGOT))/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal (ULN).
13. Creatinine clearance ≥ 30 mL/min/1.73 m\^2 calculated using the Cockcroft-Gault equation.
14. Must have archival tumor tissue available or have disease amenable to a fresh biopsy for diagnosis confirmation and correlative studies.
15. Human immunodeficiency virus (HIV)-infected individuals with undetectable viral load within 6 months are eligible for this trial. Trial participants who are on antiretroviral therapy (ART) should be on established ART for at least four weeks and have an HIV viral load less than 400 copies/mL prior to enrollment.
16. For participants with history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable and the participant should be on suppressive antiviral therapy, if indicated. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured, with HCV viral load below the level of quantification. A participant who is HCV antibody (Ab) positive but HCV ribonucleic acid (RNA) negative due to prior treatment or natural resolution is eligible for this trial. For individuals with HCV infection who are currently on treatment, they are eligible if HCV viral load below the level of quantification. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
17. participants who are on beta blockers can enroll in the trial, but discontinuation of beta-blockers should be strongly considered at the time of initiating N-803. Beta blocker use can continue per physician discretion if necessary.
\* Note: Beta-blockers or other antihypertensives may be resumed on treatment when clinically indicated.
18. Agreement to practice effective contraception for female participants of child-bearing potential and non-sterile males. Female participants of child-bearing potential must agree to use effective contraception for up to 4 months after completion of therapy, and non-sterile male participants must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (e.g., vasectomy, tubal ligation), oral and injectable contraceptives, 2 forms of barrier methods (e.g., condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and hormonal therapy. For male participants with a female partner of child-bearing potential, the female partner must also agree to use effective contraception for up to 4 months after therapy was completed.
19. Able to understand and provide a signed informed consent that fulfills the relevant institutional review board (IRB) or independent ethics committee (IEC) guidelines.
Exclusion Criteria
\* Note: Participants with previously treated brain or CNS metastases are eligible if the participant has recovered from any acute effects of surgery or radiotherapy and do not require steroids (prednisone equivalent ≥ 10 mg daily), and any whole brain radiation therapy or any stereotactic radiosurgery was completed at least 2 weeks prior to initiation of therapy.
2. Participants with a history of active autoimmune disease and on active management with immunosuppressive agents within the past 2 years
3. Participants with a history of interstitial lung disease
4. Participants with congestive heart failure (New York Heart Association class III or IV)
5. Participants on systemic intravenous or oral corticosteroid therapy (prednisone equivalent ≥ 10 mg daily) or other immunosuppressive agents such as azathioprine or cyclosporin A are excluded. For these participants, these excluded treatments must be discontinued at least 1 week prior to enrollment for recent short course use (≤ 14 days) or discontinued at least 4 weeks prior to enrollment for long term use (\> 14 days).
\* Note: The use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to enrollment and on study. participants requiring hormone replacement with corticosteroids if the steroids are administered only for the purpose of hormonal replacement or participants treated at doses ≤ 10 mg of prednisone or equivalent per day are allowed.
6. History of uncontrolled diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥ 8%.
7. Grade ≥ 2 peripheral neuropathy at baseline.
8. Radiotherapy or major surgery within 2 weeks prior to treatment start.
9. History of another significant life-limiting malignancy within 2 years prior to the first dose of study drug. Participants with non-melanoma skin cancer, curatively treated localized prostate cancer, or carcinoma in situ of any type (if complete resection was done) are allowed.
10. History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to EV and/or pembrolizumab and/or N-803.
11. Participants who have received hematopoietic stem cell transplantation or solid organ transplantation.
12. Known active keratitis or corneal ulcerations.
13. Received or will receive a live vaccine within 30 days prior to the first administration of study intervention.
\* Note: Seasonal flu vaccines that do not contain a live virus are permitted. Locally approved Coronavirus disease of 2019 (COVID-19) vaccines are permitted.
14. Pregnant and nursing women.
15. Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
16. Severe uncontrolled intercurrent illness that would limit compliance with study requirements in the judgement of the investigator.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ImmunityBio, Inc.
INDUSTRY
Vadim S Koshkin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vadim S Koshkin
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vadim Koshkin, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, San Francisco
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-07330
Identifier Type: REGISTRY
Identifier Source: secondary_id
25525
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.